2. Search Result
Search Result
Results for "

fatty acid oxidation

" in MedChemExpress (MCE) Product Catalog:

67

Inhibitors & Agonists

1

Screening Libraries

7

Biochemical Assay Reagents

21

Natural
Products

10

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139040
    2-(Tetradecylthio)acetic acid

    		PPAR Metabolic Disease
    2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .
    2-(Tetradecylthio)acetic acid
  • HY-136408
    Malonyl CoA lithium

    Malonyl coenzyme A lithium

    		 Mitochondrial Metabolism Metabolic Disease
    Malonyl CoA (Malonyl Coenzyme A) lithium is an inhibitor of carnitine palmitoyl transferase 1 (CPT1). High Malonyl CoA lithium concentrations suppress fatty acid oxidation, while low Malonyl CoA lithium concentrations are permissive for fat oxidation .
    Malonyl CoA lithium
  • HY-139285
    Arachidonic acid-alkyne

    		Others Metabolic Disease
    Arachidonic acid-alkyne is aω‑alkynyl lipid surrogates for polyunsaturated fatty acid. Arachidonic acid-alkyne has low rates of oxidation. Arachidonic acid-alkyne can be used for tracking the polyunsaturated fatty acids .
    Arachidonic acid-alkyne
  • HY-121457
    9-Nitrooleate

    		Others Cardiovascular Disease
    9-Nitrooleate is a nitrated fatty acid that is formed through NO-dependent oxidation. 9-Nitrooleate has the potential for vascular diseases research .
    9-Nitrooleate
  • HY-113256
    Linoleyl carnitine

    		Others Metabolic Disease
    Linoleyl carnitine is an acylcarnitine used to study long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and fatty acid oxidation disorders in fibroblasts .
    Linoleyl carnitine
  • HY-113434B
    5-HETE

    (±)-5-HETE

    		 Endogenous Metabolite Inflammation/Immunology
    5-HETE ((±)-5-HETE), a fatty acid, is a oxidative derivative of Arachidonic acid. 5-HETE is a mixture of 5(S)-HETE and 5(R)-HETE. 5-HETE is a potent aggregating agent that induces the aggregation of neutrophils with an IC50 value of 200 nM .
    5-HETE
  • HY-101559
    10-Nitrooleic acid

    CXA-10

    		 Others Inflammation/Immunology
    10-Nitrooleic acid (CXA-10), a nitro fatty acid, has potential effects in disease states in which oxidative stress, inflammation, fibrosis, and/or direct tissue toxicity play significant roles .
    10-Nitrooleic acid
  • HY-50202A
    Etomoxir sodium salt
    Maximum Cited Publications
    63 Publications Verification

    (R)-(+)-Etomoxir sodium salt

    		 Apoptosis Metabolic Disease Cancer
    Etomoxir((R)-(+)-Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig .
    Etomoxir sodium salt
  • HY-126015
    P053

    		Acyltransferase Metabolic Disease
    P053 is a potent, non-competitive and selective ceramide synthase 1 (CerS1) inhibitor wirh an IC50 of 0.5 μM. P053 acts as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle. Whole-body adiposity regulator .
    P053
  • HY-15259A
    CP-640186 hydrochloride
    5+ Cited Publications

    		 Acetyl-CoA Carboxylase Metabolic Disease
    CP-640186 hydrochloride is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation .
    CP-640186 hydrochloride
  • HY-15259
    CP-640186
    5+ Cited Publications

    		 Acetyl-CoA Carboxylase Metabolic Disease
    CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation .
    CP-640186
  • HY-115704
    Butyryl-L-carnitine chloride

    		Others Others
    Butyryl-L-carnitine chloride is an acylcarnitine that can be isolated from Plasma/Serum .
    Butyryl-L-carnitine chloride
  • HY-115899
    Malonyl CoA

    Malonyl coenzyme A

    		 Endogenous Metabolite Mitochondrial Metabolism Metabolic Disease
    Malonyl CoA is a substrate for fatty acid biosynthesis and an inhibitor of fatty acid oxidation. Malonyl CoA is also a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1 .
    Malonyl CoA
  • HY-130060
    12(S)-HETrE

    		Others Cardiovascular Disease
    12(S)-HETrE is a fatty acid metabolite that inhibits platelet aggregation. 12(S)-HETrE can be used in thrombosis-related research .
    12(S)-HETrE
  • HY-113201
    Tetradecanoylcarnitine

    		Endogenous Metabolite Metabolic Disease
    Tetradecanoylcarnitine is a human carnitine involved in β-oxidation of long-chain fatty acids.
    Tetradecanoylcarnitine
  • HY-W104819
    4-Hydroxyphenylglyoxylate

    4-Hydroxyphenylglyoxylic acid; 4-HPGA

    		 Others Metabolic Disease
    4-Hydroxyphenylglyoxylate (4-Hydroxyphenylglyoxylic acid) is an inhibitor of carnitine palmitoyltransferase I (CPT I). 4-Hydroxyphenylglyoxylate can be used to study sensitivity changes in CPT I of liver mitochondria and fatty acid oxidation by isolated hepatocytes. 4-Hydroxyphenylglyoxylate can inhibits fatty acid oxidation .
    4-Hydroxyphenylglyoxylate
  • HY-141473
    Malonyl CoA tetralithium

    Malonyl coenzyme A tetralithium

    		 Endogenous Metabolite Mitochondrial Metabolism Metabolic Disease
    Malonyl CoA (Malonyl coenzyme A) tetralithium is a substrate for fatty acid biosynthesis and an inhibitor of fatty acid oxidation. Malonyl CoA tetralithium is also a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1 .
    Malonyl CoA tetralithium
  • HY-N0458
    Pedunculoside

    		Fatty Acid Synthase (FASN) Metabolic Disease
    Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .
    Pedunculoside
  • HY-113261
    Oleoylcarnitine

    		Endogenous Metabolite Metabolic Disease Cancer
    Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation .
    Oleoylcarnitine
  • HY-50202
    Etomoxir
    Maximum Cited Publications
    63 Publications Verification

    (R)-(+)-Etomoxir

    		 Apoptosis Metabolic Disease Cancer
    Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
    Etomoxir
  • HY-130319A
    9-HEPE

    		PPAR Cardiovascular Disease Metabolic Disease
    9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
    9-HEPE
  • HY-126221A
    (R)-Aminocarnitine

    Emeriamine

    		 Biochemical Assay Reagents Metabolic Disease
    (R)-Aminocarnitine (Emeriamine) is a fatty acid oxidation inhibitor. (R)-Aminocarnitine reduces hyperglycaemia and ketosis. (R)-Aminocarnitine can be used in the study of metabolic diseases .
    (R)-Aminocarnitine
  • HY-128851
    Coenzyme A

    		Fatty Acid Synthase (FASN) Endogenous Metabolite Metabolic Disease
    Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids .
    Coenzyme A
  • HY-128851A
    Coenzyme A trilithium

    		Endogenous Metabolite Fatty Acid Synthase (FASN) Metabolic Disease
    Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids .
    Coenzyme A trilithium
  • HY-128851B
    Coenzyme A sodium

    		Endogenous Metabolite Fatty Acid Synthase (FASN) Metabolic Disease
    Coenzyme A (CoASH) sodium is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids .
    Coenzyme A sodium
  • HY-113166
    Dodecanoylcarnitine

    		Endogenous Metabolite Metabolic Disease
    Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.
    Dodecanoylcarnitine
  • HY-B1453
    (±)-Carnitine chloride
    1 Publications Verification

    DL-Carnitine chloride

    		 Reactive Oxygen Species Metabolic Disease
    (±)-Carnitine chloride exists in two isomers, known as D and L. L-carnitine plays an essential role in the β-oxidation of fatty acids and also shows antioxidant, and anti-inflammatory activities.
    (±)-Carnitine chloride
  • HY-112540B
    Acetoacetic acid sodium
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Acetoacetic acid sodium is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. Acetoacetic acid sodium induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes .
    Acetoacetic acid sodium
  • HY-135425
    10,12-Tricosadiynoic acid
    3 Publications Verification

    		 Acyltransferase Metabolic Disease
    10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism . 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    10,12-Tricosadiynoic acid
  • HY-108433
    CPT2

    Carnitine palmitoyltransferase 2

    		 Apoptosis MDM-2/p53 Metabolic Disease Cancer
    CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .
    CPT2
  • HY-W018026
    Oxfenicine

    L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842

    		 Others Metabolic Disease
    Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acid in heart. Oxfenicine protects heart from necrotic tissue damage during ischaemia .
    Oxfenicine
  • HY-W012550
    D-Carnitine

    		Parasite Infection
    D-Carnitine is an orally available isomer of the essential nutrient L-carnitine that promotes long-chain fatty acid transport into the mitochondrial matrix for beta-oxidation. D-Carnitine has antiparasitic activity .
    D-Carnitine
  • HY-B1453S1
    (±)-Carnitine-d9 chloride

    DL-Carnitine-d9 (chloride)

    		 Reactive Oxygen Species Metabolic Disease
    (±)-Carnitine-d9 (chloride) is the deuterium labeled (±)-Carnitine chloride. (±)-Carnitine chloride exists in two isomers, known as D and L. L-carnitine plays an essential role in the β-oxidation of fatty acids and also shows antioxidant, and anti-inflammatory activities.
    (±)-Carnitine-d9 chloride
  • HY-B0399
    L-Carnitine
    5+ Cited Publications

    (R)-Carnitine; Levocarnitine

    		 Endogenous Metabolite Neurological Disease Cancer
    L-Carnitine ((R)-Carnitine), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine is an antioxidant. L-Carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism .
    L-Carnitine
  • HY-B2246
    L-Carnitine hydrochloride
    5+ Cited Publications

    (R)-Carnitine hydrochloride; Levocarnitine hydrochloride

    		 Endogenous Metabolite Metabolic Disease Cancer
    L-Carnitine hydrochloride ((R)-Carnitine hydrochloride), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine hydrochloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine hydrochloride is an antioxidant. L-Carnitine hydrochloride can ameliorate metabolic imbalances in many inborn errors of metabolism .
    L-Carnitine hydrochloride
  • HY-N10898
    (-)-Dihydroguaiaretic acid

    		Lipoxygenase Inflammation/Immunology Cancer
    (-)-Dihydroguaiaretic acid is a Lipoxygenase inhibitor that has antioxidant activity. (-)-Dihydroguaiaretic acid inhibits the oxidation of unsaturated fatty acids and removes free radicals. (-)-Dihydroguaiaretic acid also has anticancer activity with an IC50 value of 7.49 μM (A549 cells) .
    (-)-Dihydroguaiaretic acid
  • HY-21268
    Methyl linolenate
    1 Publications Verification

    Linolenic acid methyl ester

    		 Others Metabolic Disease
    Methyl linolenate is a polyunsaturated fattly acid (PUFA). Methyl linolenate has an anti-melanogenesis activity with an IC50 of 60 μM. Methyl linolenate can also be used for studies of the mechanisms and prevention of oxidation/peroxidation of unsaturated fatty acids .
    Methyl linolenate
  • HY-116722
    (2E)-4-Hydroperoxy-2-nonenal

    		Reactive Oxygen Species Inflammation/Immunology
    (2E)-4-Hydroperoxy-2-nonenal is a lipid peroxidation product derived from oxidized ω-6 polyunsaturated fatty acids, and can be used as a marker of oxidative stress .
    (2E)-4-Hydroperoxy-2-nonenal
  • HY-108571
    CP-775146

    		PPAR Metabolic Disease
    CP-775146 is a selective PPARα agonist that binds strongly to the PPARα ligand. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .
    CP-775146
  • HY-126042
    (±)-Lisofylline

    (±)-Lisophylline

    		 Others Metabolic Disease Inflammation/Immunology
    (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research .
    (±)-Lisofylline
  • HY-112653A
    (±)8-HETE

    		Endogenous Metabolite Metabolic Disease
    (±)8-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of Arachidonic acid (HY-109590). The biological activity of (±)8-HETE is likely to resemble that of its constituent enantiomers (8(R)-HETE and 8(S)-HETE).
    (±)8-HETE
  • HY-139577
    Ninerafaxstat

    IMB-1018972; IMB-101

    		 Mitochondrial Metabolism Metabolic Disease Cancer
    Ninerafaxstat (IMB-1018972) is a novel mitotropic agent. Ninerafaxstat increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat can be used for the research of cardiovascular diseases .
    Ninerafaxstat
  • HY-21268S
    Methyl linolenate-13C18

    		Isotope-Labeled Compounds Others
    Methyl linolenate- 13C18 is the 13C labeled Methyl linolenate[1]. Methyl linolenate is a polyunsaturated fattly acid (PUFA). It is used in studies on the mechanisms and prevention of oxidation/peroxidation of unsaturated fatty acids[2][3]. The IC50 is 60 uM[4].
    Methyl linolenate-13C18
  • HY-139577A
    Ninerafaxstat trihydrochloride

    MB-1018972 trihydrochloride; IMB-101 trihydrochloride

    		 Mitochondrial Metabolism Metabolic Disease Cancer
    Ninerafaxstat (IMB-1018972) trihydrochloride is a novel mitotropic agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat trihydrochloride can be used for the research of cardiovascular diseases .
    Ninerafaxstat trihydrochloride
  • HY-B0399S
    L-Carnitine-d9

    (R)-Carnitine-d9; Levocarnitine-d9

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Carnitine-d9 is the deuterium labeled L-Carnitine. L-Carnitine (Levocarnitine) is an endogenous molecule involved in fatty acid metabolism, biosynthesized within the human body using amino acids: L-lysine and L-methionine, as substrates. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2].
    L-Carnitine-d9
  • HY-135087
    Caprylic/Capric Triglyceride
    1 Publications Verification

    		 Biochemical Assay Reagents Others
    Caprylic/Capric Triglyceride is the triglycerides and esters prepared from fractionated vegetable oil sources and fatty acids from coconuts and palm kernel oils. Caprylic/Capric Triglyceride possesses excellent oxidation stability. Caprylic/Capric Triglyceride is used as a food additive and used in cosmetics .
    Caprylic/Capric Triglyceride
  • HY-B2246S
    L-Carnitine-d9 chloride

    (R)-Carnitine-d9 (chloride); Levocarnitine-d9 (chloride)

    		 Endogenous Metabolite Metabolic Disease
    L-Carnitine-d9 (chloride)e is the deuterium labeled L-Carnitine chloride. L-Carnitine chloride, a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine chloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine chloride is an antioxidant. L-Carnitine chloride can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2][3].
    L-Carnitine-d9 chloride
  • HY-130502
    Cholesterol 5beta,6beta-epoxide

    Cholesterol beta-epoxide

    		 Biochemical Assay Reagents Others
    Cholesterol 5beta,6beta-epoxide is an oxidative metabolite of cholesterol formed by free-radical and non-radical oxidation of cholesterol at the 5,6 double bond. Induces lactate dehydrogenase (LDH) release and apoptosis in macrophage-differentiated U937 cells. Cholesterol 5beta,6beta-epoxide has been found in human fatty streaks and advanced atherosclerotic lesions, but not in normal aortic tissue .
    Cholesterol 5beta,6beta-epoxide
  • HY-153392
    TYA-018

    		Oxidative Phosphorylation HDAC Cardiovascular Disease
    TYA-018 is an orally active, potent and highly selective HDAC6 inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation .
    TYA-018
  • HY-17401
    Ranolazine dihydrochloride
    3 Publications Verification

    CVT 303 dihydrochloride; RS 43285

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: